Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Non Operating Income (2016 - 2023)

RedHill Biopharma has reported Non Operating Income over the past 12 years, most recently at $47.5 million for Q2 2023.

  • Quarterly Non Operating Income rose 558.85% to $47.5 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was -$8.9 million through Jun 2023, up 72.05% year-over-year, with the annual reading at -$138000.0 for FY2025, 102.02% down from the prior year.
  • Non Operating Income was $47.5 million for Q2 2023 at RedHill Biopharma, up from -$21.2 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $47.5 million in Q2 2023 and troughed at -$63.9 million in Q4 2022.
  • The 5-year median for Non Operating Income is $2.1 million (2019), against an average of -$1.5 million.
  • Year-over-year, Non Operating Income soared 46522.22% in 2020 and then plummeted 739.07% in 2021.
  • A 5-year view of Non Operating Income shows it stood at -$73000.0 in 2019, then surged by 6432.88% to $4.6 million in 2020, then plummeted by 739.07% to -$29.5 million in 2021, then plummeted by 116.18% to -$63.9 million in 2022, then soared by 174.36% to $47.5 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Non Operating Income are $47.5 million (Q2 2023), -$21.2 million (Q1 2023), and -$63.9 million (Q4 2022).